
Ambicare Health Limited
Wearable LED phototherapy devices for dermatological conditions.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
* | £495k | Early VC | |
Total Funding | 000k |
GBP | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2018 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | (72 %) | 11746 % | (29 %) | (6 %) | (53 %) | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (6956 %) | (50965 %) | (426 %) | (432 %) | (357 %) | (424 %) | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (6451 %) | (46775 %) | (416 %) | (438 %) | (368 %) | (403 %) | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Ambicare Health Limited operates as a designer, developer, and distributor of medical-grade LED phototherapy devices for skincare. The company was established in 2004 as a spin-out from the University of St Andrews, NHS Tayside, and Scottish Health Innovations Ltd. . The scientific foundation of the company stems from the pioneering work of its founders, Professor Ifor Samuel and Professor James Ferguson. . Professor Samuel, holding a PhD in Physics from Cambridge, is the founder of the Organic Semiconductor Centre at the University of St Andrews, focusing on organic semiconductors and their applications in medicine. . Professor Ferguson is a consultant dermatologist from Ninewells Hospital, recognized for his significant contributions to photodermatology and the establishment of the photobiology unit at the hospital. .
The firm's business model encompasses both direct-to-consumer sales under its proprietary brand, LUSTRE® Skin, and private label services for other brands. Its initial product, Ambulight, was a hospital-based LED therapy for treating non-melanoma skin cancer. . Leveraging this core technology, the company expanded into the consumer market, targeting common dermatological concerns such as acne and signs of aging. . Revenue is generated through the sale of these devices and related skincare products. The product portfolio includes a range of wearable light therapy devices designed for at-home use. . A key patented feature allows users to wear the device, ensuring consistent and convenient light delivery to the skin. .
The LUSTRE® ClearSkin product line, which includes devices like the SOLO, TRIO, and full-face masks, utilizes different wavelengths of light to address specific skin issues. . Blue light is used to target acne-causing bacteria, while red and near-infrared light aim to reduce inflammation, stimulate collagen, and improve skin texture. . These products have obtained CE certification for sale in the European Economic Area and FDA clearance for over-the-counter sales in the US for treating mild-to-moderate acne. . The company also offers supplementary products, such as skin tablets, that work internally to address skin concerns. . Ambicare Health has secured significant investment funding and distributes its products globally through various channels, including its own website and major retailers like Boots. .
Keywords: LED phototherapy, dermatology, wearable medical devices, skincare technology, acne treatment, skin rejuvenation, anti-aging, photodynamic therapy, blue light therapy, red light therapy, private label skincare, St Andrews University spin-out, Ninewells Hospital, Ifor Samuel, James Ferguson, LUSTRE Skin, Ambulight, home-use medical devices, non-invasive treatment, CE certified, FDA cleared